Navigation Links
Little known DNA repair enzyme may be a tumor suppressor gene

Use of the amino acid supplement L-arginine following a heart attack does not improve certain cardiac functions and measurements and may be associated with an increased risk of death, according to a study in the January 4 issue of JAMA.

L-arginine is a widely available dietary supplement and is publicized as having benefits for patients with hypertension, angina, heart failure and sexual dysfunction, according to background information in the article. Prior studies suggest that L-arginine has the potential to reduce vascular (blood vessel) stiffness.

Steven P. Schulman, M.D., of Johns Hopkins Medical Institutions, Baltimore, and colleagues conducted the Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) clinical trial to test whether administering L-arginine to patients following a first ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack) over a 6-month period would decrease vascular stiffness and improve ejection fraction (a measure of how much blood the left ventricle of the heart pumps out with each contraction).

The randomized, double-blind, placebo-controlled trial included 153 STEMI patients; 77 were 60 years or older. Participants were enrolled from February 2002 to June 2004. Patients were randomly assigned to receive L-arginine (goal dose of 3 g three times a day) or matching placebo for six months.

The researchers found: "The VINTAGE MI study demonstrated that 6 months of L-arginine added to standard postinfarct medications did not reduce noninvasive measures of vascular stiffness, improve ejection fraction, or improve clinical outcomes. To the contrary, we noted a possible increased risk of death in older patients after infarction while taking L-arginine compared with those taking a placebo, leading to the early termination of the study. These findings have broad public health implications given the increasing availability and use of L-argin ine in patients with and without established cardiovascular diseases."

Death occurred in 6 patients (8.6 percent) in the L-arginine group died during the 6-month study period vs. none in the placebo group.

"In conclusion, L-arginine therapy should not be given to patients following a myocardial infarction. It neither alters noninvasive measures of vascular stiffness nor improves left ventricular function. L-arginine therapy in older patients with diffuse atherosclerosis may worsen clinical outcomes," the authors write.


'"/>

Source:University of Pittsburgh Medical Center


Related biology news :

1. Earliest European Farmers Left Little Genetic Mark On Modern Europe
2. A genes first kiss sets off that affair known as puberty
3. Scientists identify molecule that regulates well-known tumor suppressor
4. Butterfly migration could be largest known
5. Study: Well-known protein helps stem cells become secretory cells
6. Mechanism for the captation of nutrients in plants- unknown to date
7. Team of international scientists departs today to discover the unknown in Chinas Himalayan region
8. Scientists develop a way to make the deadliest toxin known even more toxic
9. Scientists re-engineer a well-known antibiotic to counter drug resistance
10. Can you hear me now? Scientists find previously unknown receptors on adult stem cells
11. Marathon mice elucidate little-known muscle type
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... ... April 25, 2017 , ... As part of the Stago EdVantage Virtual ... testing for DIC in order to illuminate this clinical problem for people unfamiliar with ... patients resulting in a high degree of morbidity and mortality. DIC is a confusing ...
(Date:4/25/2017)... PROVIDENCE, R.I. , April 25, 2017 /PRNewswire/ ... EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology ... in autoimmune disease and allergy. Tregitopes, ... discovered in human immunoglobulin by EpiVax CEO ... Martin. Similar to intravenous immunoglobulin G, an autoimmune ...
(Date:4/25/2017)... ... April 25, 2017 , ... Leaders of Quorum Review IRB ... in multiple sessions at this week’s Association of Clinical Research Professionals (ACRP) 2017 ... in clinical research. , "We are excited to present subject matter expertise on topics ...
(Date:4/21/2017)... DENVER, COLORADO (PRWEB) , ... April 21, 2017 ... ... Manufacturing. Awards recognized outstanding manufactures in 10 categories with over 30 nominees and ... Women in Manufacturing presented the new award and the event was hosted by ...
Breaking Biology Technology: